Alternate-Day Buprenorphine Administration. Phase II - 4
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Amass, bickel, Crean, Blake, Higgins (in press). Alternate day buprenorphine dosing as efficacious and preferred to daily dosing in opioid dependent humans. Psychopharmacology. Amass, Bickel, Crean, Blake, Higgins. (in press) Alternate day buprenorphine dosing as efficacious and preferred to daily dosing in opioid dependent humans. Psychopharmacology